China Resources Pharmaceutical Group (HKSE:03320) NonCurrent Deferred Liabilities: HK$0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03320 China Resources Pharmaceutical Group Ltd HKSE:03320
90 GF Score
Price HK$4.65
GF Value HK$6.03
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group NonCurrent Deferred Liabilities?

China Resources Pharmaceutical Group HKSE:03320 -1.17% 90 NonCurrent Deferred Liabilities is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:03320 with a GF Score™ of 90/100 and a GF Value™ of HK$6.03 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

China Resources Pharmaceutical Group's non-current deferred liabilities for the quarter that ended in Dec. 2025 was HK$0 Mil.

China Resources Pharmaceutical Group NonCurrent Deferred Liabilities Related Terms

China Resources Pharmaceutical Group NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for China Resources Pharmaceutical Group's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group NonCurrent Deferred Liabilities Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China Resources Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:03320
90GF Score
China Resources Pharmaceutical Group Ltd HKSE:03320
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of HK$0 Mil mean?
China Resources Pharmaceutical Group (HKSE:03320) has a NonCurrent Deferred Liabilities of HK$0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's NonCurrent Deferred Liabilities too high?
China Resources Pharmaceutical Group's current NonCurrent Deferred Liabilities is HK$0 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's NonCurrent Deferred Liabilities compare to ZTS?
China Resources Pharmaceutical Group's NonCurrent Deferred Liabilities of HK$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current NonCurrent Deferred Liabilities is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (HKSE:03320) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$6.03, compared to a current price of HK$4.65 — trading 22.9% below its estimated fair value. The current NonCurrent Deferred Liabilities is HK$0 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For China Resources Pharmaceutical Group (HKSE:03320), the current NonCurrent Deferred Liabilities is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Pharmaceutical Group (HKSE:03320) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of HK$4.65 is trading 22.9% below its estimated GF Value™ of HK$6.03. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for HKSE:03320:

  • NonCurrent Deferred Liabilities: HK$0 Mil
  • GF Value™: HK$6.03 vs. price of HK$4.65 (22.9% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the HKSE:03320 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Pharmaceutical Group Business Description

Other Exchanges 640:Germany
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
90GF Score

Get the complete analysis for HKSE:03320

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.65
Price
HK$6.03
GF Value